4/A: QuidelOrtho Director Amends SEC Filing to Correct Vesting Dates for Restricted Stock Units

QuidelOrtho Corp. Director Ann D. Rhoads has filed an amended Form 4 to correct the vesting schedule for restricted stock units granted on May 29, 2025.

Summary

• Ann D. Rhoads, a Director of QuidelOrtho Corp. (QDEL), filed an amended Form 4 (4/A) on June 3, 2025.
• The amendment corrects the vesting dates for restricted stock units (RSUs) granted to her on May 29, 2025, with the original Form 4 having been filed on June 2, 2025.
• The filing details the grant of 6,829 Restricted Stock Units (Equity Grant) and 325 Restricted Stock Units (Premium), both of which are scheduled to vest on May 29, 2026.
• Additionally, 1,626 Restricted Stock Units (Converted) were granted, received in lieu of cash payments for retainer and Board service fees under a deferred compensation program.
• The corrected vesting schedule for the 1,626 converted RSUs is as follows: 406 shares vested on May 29, 2025; 406 shares will vest on August 29, 2025; 407 shares will vest on November 29, 2025; and 407 shares will vest on February 28, 2026.
• Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

Sentiment

Score: 5

Explanation: The document is a routine amendment to correct administrative details regarding director compensation. It is neutral in sentiment, neither indicating significant positive nor negative operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Ann D. Rhoads aligns her interests with those of shareholders, promoting long-term commitment.
• The company's deferred compensation program for non-employee directors, allowing equity in lieu of cash, is a positive mechanism for attracting and retaining board talent.

Negatives

• The necessity of filing an amendment (Form 4/A) to correct previously reported vesting dates indicates a minor administrative oversight in the initial filing.

Future Outlook

The document specifies future vesting dates for the granted Restricted Stock Units, with portions scheduled to vest on August 29, 2025, November 29, 2025, February 28, 2026, and May 29, 2026.

Management Comments

• The filing was signed by Phillip S. Askim, attorney-in-fact for Ann D. Rhoads.

Industry Context

This filing is a routine insider transaction report (Form 4/A) detailing a director's equity compensation. It does not provide information relevant to broader industry trends or competitive dynamics within the diagnostics or medical device sectors where QuidelOrtho operates.

Comparison to Industry Standards

• The practice of granting Restricted Stock Units (RSUs) to non-employee directors as part of their compensation, often in lieu of cash, is a common corporate governance practice across various industries, including healthcare and diagnostics. This aligns director incentives with long-term shareholder value, consistent with standard industry compensation models.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Ann D. Rhoads, a director, constitutes a related party transaction as it involves compensation to a member of the company's board. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant of Restricted Stock Units may result in minor future dilution upon vesting and conversion to common stock, but it also serves to align the director's interests with shareholder value.

Next Steps

• Vesting of 406 converted Restricted Stock Units on August 29, 2025.
• Vesting of 407 converted Restricted Stock Units on November 29, 2025.
• Vesting of 407 converted Restricted Stock Units on February 28, 2026.
• Vesting of 6,829 Equity Grant RSUs and 325 Premium RSUs on May 29, 2026.

Key Dates

Keywords

QuidelOrtho Corp, QDEL, SEC Form 4/A, Restricted Stock Units, RSU, Director compensation, Equity grant, Vesting schedule, Insider transaction, Ann D. Rhoads